Oculis Holding AG (OCS) Income from Continuing Operations (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Income from Continuing Operations of 37094432.0 for Q1 2026, little changed year-over-year from 37264809.33 in Q1 2025, and down 151.01% quarter-over-quarter from 72715485.96 in Q4 2025.
Oculis Holding AG (OCS) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Oculis Holding AG's Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 37094432.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations changed 0.46% year-over-year to 37094432.0; the TTM figure through Mar 2026 stood at 21033180158.89 (up 9.94% YoY), while the FY2025 annual figure was 119803537.24, down 22.42% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 37094432.0, down from 72715485.96 in the prior quarter.
- The five-year high for Income from Continuing Operations was 72715485.96 in Q4 2025, with the low at 23261892784.97 in Q3 2024.
- The 5-year median for Income from Continuing Operations is 21477057.43 (2023), against an average of 2783551865.92.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations sank 116344.35% in 2024, then jumped 318.67% in 2025.
- Oculis Holding AG's Income from Continuing Operations stood at 9561219.83 in 2022, then tumbled by 47.68% to 14120114.78 in 2023, then plunged by 135.51% to 33253672.96 in 2024, then surged by 318.67% to 72715485.96 in 2025, then tumbled by 151.01% to 37094432.0 in 2026.
- Business Quant data shows OCS's Income from Continuing Operations at 37094432.0 in Q1 2026, 72715485.96 in Q4 2025, and 21038093019.56 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | -12.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.16 Mn |
| Mar 31, 2026 | -37.09 Mn |
| Dec 31, 2025 | 72.72 Mn |
| Sep 30, 2025 | -21.04 Bn |
| Jun 30, 2025 | -30.71 Mn |
| Mar 31, 2025 | -36.93 Mn |
| Dec 31, 2024 | -33.25 Mn |
| Sep 30, 2024 | -23.26 Bn |
| Jun 30, 2024 | -22.98 Mn |
| Mar 31, 2024 | -18.37 Mn |
| Dec 31, 2023 | -14.12 Mn |
| Sep 30, 2023 | -19.98 Mn |
| Jun 30, 2023 | -14.07 Mn |
| Mar 31, 2023 | -49.48 Mn |
| Dec 31, 2022 | -9.56 Mn |
| Sep 30, 2022 | -10.29 Mn |
| Jun 30, 2022 | -12.73 Mn |